Open AccessChemotherapy plus atezolizumab for a patient with small cell lung cancer undergoing haemodialysis: a case report and review of literature
Author(s) -
Imaji Mihoko,
Fujimoto Daichi,
Kato Mai,
Tanaka Masanori,
Furuta Katsuyuki,
Yamamoto Nobuyuki
Publication year - 2021
Publication title -
respirology case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.304
H-Index - 9
ISSN - 2051-3380
DOI - 10.1002/rcr2.741
Subject(s) - carboplatin , atezolizumab , medicine , etoposide , leukopenia , chemotherapy , lung cancer , neutropenia , oncology , urology , surgery , cancer , pembrolizumab , cisplatin , immunotherapy
Little is known about the safety of chemotherapy plus atezolizumab for patients with extensive‐stage small cell lung cancer (ES‐SCLC) undergoing haemodialysis (HD). An 80‐year‐old male received carboplatin [area under the concentration‐time curve (AUC) = 5 on day 1], etoposide (40 mg/m 2 on days 1, 2, and 3), and atezolizumab (1200 mg/body on day 1) as the first‐line therapy for ES‐SCLC. He was undergoing HD thrice a week for seven years. HD was provided 16 h after carboplatin administration. During the first cycle, grade 4 neutropenia (neutrophil count: 74/μL) and leukopenia (white blood cell count: 680/μL) occurred. Therefore, chemotherapy was administered with a reduced dose of carboplatin (AUC = 4) and etoposide (30 mg/m 2 ) from the second to fourth cycles. After four cycles, no severe non‐haematological adverse events occurred, showing a remarkable response. We conclude that the carboplatin, etoposide, and atezolizumab combination can be safely administered to cancer patients undergoing HD.